Coeptis Therapeutics Holdings, Inc. (COEP) Key Statistics & Financial Ratios

Coeptis Therapeutics Holdings, Inc. (COEP) — Price $10.99 TechnologySoftware - Services — NASDAQ

Latest reported results:

Key statistics dashboard for Coeptis Therapeutics Holdings, Inc. (COEP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.

Stock Data

Price$10.99
Market Cap$39M
Enterprise Value$23.1M
Beta-0.43
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-6.11
Price / Book4.13
P/S13.81
EV/EBITDA-1.12
EV/Sales8.27
EV/FCF-5.72
P/FCF-9.55
Earnings Yield-4.03%
FCF Yield-10.47%
Dividend Yield0.00%

Profitability

Gross Margin16.78%
EBIT Margin-277.97%
EBITDA Margin-740.40%
Operating Margin-792.87%
Net Margin-788.80%
Return on Equity-48.21%
Return on Assets-16.40%
Return on Invested Capital-16.68%
Return on Capital Employed-16.74%

Financial Health

Current Ratio7.66
Quick Ratio7.66
Cash Ratio7.64
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA0.75
Interest Coverage-43.64
Piotroski F-Score6
Altman Z-Score7.84

Per-Share Data

Revenue per share0.06
Book Value per share2.66
Cash per share0.31
FCF per share-0.08
Tangible Book Value per share0.51
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
Total analysts1
Avg rating (1-5)1.00

Related companies: CUE · EQ · IPSC · KPTI · MDCX · NRXP · OSTX

Explore sector: Technology · Software - Services

More sections of COEP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks